The present disclosure provides genetically modified antibody-producing cells comprising edited chromosomal sequences associated with immunoglobulin heavy chain constant region, the IgH locus. In particular, these cells are generated using a CRISPR/Cas 9-mediated editing process. The disclosure also provides specific guide RNA (gRNA) guide sequences that target the chromosomal sequence of immunoglobulin heavy chain constant region in the Switch regions.

Disclosed are an attenuation system and the use thereof for attenuating plasmodia, specifically the use of an EF1g gene for attenuating plasmodia. The attenuation system regulates the expression or degradation of the EF1g gene by using a regulatory system, thereby controlling the growth of plasmodia and achieving the attenuation of plasmodia.

Disclosed are an attenuation system and the use thereof for attenuating plasmodia, specifically the use of an EF1g gene for attenuating plasmodia. The attenuation system regulates the expression or degradation of the EF1g gene by using a regulatory system, thereby controlling the growth of plasmodia and achieving the attenuation of plasmodia.

Provided herein are methods of producing cell lines with stable expression of a transgene by removal of CpG motifs. In further methods, there are provided methods for cell lines with stable expression of a transgene by driving expression by novel promoters or by tagging endogenous genes.

Provided herein are methods of producing cell lines with stable expression of a transgene by removal of CpG motifs. In further methods, there are provided methods for cell lines with stable expression of a transgene by driving expression by novel promoters or by tagging endogenous genes.

The present invention relates to nucleic acid molecules comprising a nucleic acid sequence encoding a membrane-bound biotin mimetic peptide (BMP) or biotin acceptor peptide (BAP). The invention also relates to a method for selection of high producer cells secreting a protein of interest.

The present invention relates to nucleic acid molecules comprising a nucleic acid sequence encoding a membrane-bound biotin mimetic peptide (BMP) or biotin acceptor peptide (BAP). The invention also relates to a method for selection of high producer cells secreting a protein of interest.

The present invention relates to a bioactive agent capable of increasing the intracellular concentration and/or activity of Hsp70 for use in the treatment of a lysosomal storage disease which arise from a defect in an enzyme whose activity is not directly associated with the presence of lysosomal BMP as a co-factor; such as glycogen storage diseases, gangliosidoses, neuronal ceroid lipofuscinoses, cerebrotendinous cholesterosis, Wolman's disease, cholesteryl ester storage disease, disorders of glycosaminoglycan metabolism, mucopolysaccharidoses, disorders of glycoprotein metabolism, mucolipidoses, aspartylglucosaminuria, fucosidosis, mannosidoses, and sialidosis type II.

Provided herein are methods and compositions for modifying cells. Provided herein are methods and compositions for modifying an organism of a cell. Provided herein are methods and compositions for introducing polynucleotides and/or polypeptides into a nucleus of a cell.

Provided herein are recombinant cardiomyocytes and cardiomyocyte cell lines expressing human Ether-a-go-go Related Gene (hERG) potassium ion channel, including, for example, stable cell lines, that comprise a transfected or transduced nucleic acid sequence encoding hERG. Also provided herein are methods of using the recombinant cardiomyocytes and cardiomyocyte cell lines expressing hERG for screening compounds for cardiotoxicity, including methods for determining the activity of compounds to inhibit hERG.